Is NAMS or NAMSW more undervalued in 2026?

CirclFi compares NewAmsterdam Pharma Company N.V (NAMS) and NewAmsterdam Pharma Company N.V (NAMSW) using 13 institutional-grade valuation models. NAMS has a Quality of Company score of 2.3/10 while NAMSW scores 2.2/10.

Which is a better buy — NAMS or NAMSW?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NAMS and NAMSW valuations compare?

NAMS at $33.68 and NAMSW at $25.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NAMS vs NAMSW Valuation Comparison 2026 — Intrinsic Value Analysis

NAMS

Pharmaceutical Preparations

NewAmsterdam Pharma Company N.V

Quality

2.3

out of 10

Value Trap

—

Price

$33.68

Last close

Models

12/13

Active

NAMSW

Pharmaceutical Preparations

NewAmsterdam Pharma Company N.V

Quality

2.2

out of 10

Value Trap

—

Price

$25.00

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	NAMS Fair Value	NAMS Upside	NAMSW Fair Value	NAMSW Upside
Bayesian DCF	Intrinsic	$7.81	-76.8%	—	—
Earnings Power Value	Intrinsic	$18.09	-39.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$10.41	-69.1%	$3.60	-83.1%
Dynamic NAV	Asset-Based	$2.99	-91.1%	$6.79	-68.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAMS vs NAMSW — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAMS vs NAMSW — Which Stock Is More Undervalued?

NAMS scores higher with a 2.3/10 quality rating vs NAMSW's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewAmsterdam Pharma Company N.V (NAMS) and NewAmsterdam Pharma Company N.V (NAMSW) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAMS currently trades at $33.68 with a QOC of 2.3/10, while NAMSW trades at $25.00 with a QOC of 2.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).